Search

Your search keyword '"Mendrzyk, Regina"' showing total 24 results
Start Over Author "Mendrzyk, Regina"
24 results on '"Mendrzyk, Regina"'

1. Actively personalized vaccination trial for newly diagnosed glioblastoma

Author

Hilf, Norbert, Kuttruff-Coqui, Sabrina, Frenzel, Katrin, Bukur, Valesca, Stevanović, Stefan, Gouttefangeas, Cécile, Platten, Michael, Tabatabai, Ghazaleh, Dutoit, Valerie, van der Burg, Sjoerd H., thor Straten, Per, Martínez-Ricarte, Francisco, Ponsati, Berta, Okada, Hideho, Lassen, Ulrik, Admon, Arie, Ottensmeier, Christian H., Ulges, Alexander, Kreiter, Sebastian, von Deimling, Andreas, Skardelly, Marco, Migliorini, Denis, Kroep, Judith R., Idorn, Manja, Rodon, Jordi, Piró, Jordi, Poulsen, Hans S., Shraibman, Bracha, McCann, Katy, Mendrzyk, Regina, Löwer, Martin, Stieglbauer, Monika, Britten, Cedrik M., Capper, David, Welters, Marij J. P., Sahuquillo, Juan, Kiesel, Katharina, Derhovanessian, Evelyna, Rusch, Elisa, Bunse, Lukas, Song, Colette, Heesch, Sandra, Wagner, Claudia, Kemmer-Brück, Alexandra, Ludwig, Jörg, Castle, John C., Schoor, Oliver, Tadmor, Arbel D., Green, Edward, Fritsche, Jens, Meyer, Miriam, Pawlowski, Nina, Dorner, Sonja, Hoffgaard, Franziska, Rössler, Bernhard, Maurer, Dominik, Weinschenk, Toni, Reinhardt, Carsten, Huber, Christoph, Rammensee, Hans-Georg, Singh-Jasuja, Harpreet, Sahin, Ugur, Dietrich, Pierre-Yves, and Wick, Wolfgang

Published
2019
Full Text
View/download PDF

2. Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

3. Data from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

4. Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

5. Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

9. Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

10. Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, primary, Andersson, Borje S., primary, Mendrzyk, Regina, primary, Alpert, Amir, primary, Wagner, Claudia, primary, Nowak, Anna, primary, Aslan, Katrin, primary, Satelli, Arun, primary, Richter, Fabian, primary, Kuttruff-Coqui, Sabrina, primary, Schoor, Oliver, primary, Fritsche, Jens, primary, Coughlin, Zoe, primary, Mohamed, Ali S., primary, Sieger, Kerry, primary, Norris, Becky, primary, Ort, Rita, primary, Beck, Jennifer, primary, Vo, Henry Hiep, primary, Hoffgaard, Franziska, primary, Ruh, Manuel, primary, Backert, Linus, primary, Wistuba, Ignacio I., primary, Fuhrmann, David, primary, Ibrahim, Nuhad K., primary, Morris, Van Karlyle, primary, Kee, Bryan K., primary, Halperin, Daniel M., primary, Nogueras-Gonzalez, Graciela M., primary, Kebriaei, Partow, primary, Shpall, Elizabeth J., primary, Vining, David, primary, Hwu, Patrick, primary, Singh, Harpreet, primary, Reinhardt, Carsten, primary, Britten, Cedrik M., primary, Hilf, Norbert, primary, Weinschenk, Toni, primary, Maurer, Dominik, primary, and Walter, Steffen, primary

Published
2023
Full Text
View/download PDF

12. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Author

Tsimberidou, Apostolia M., primary, Guenther, Kerstin, additional, Andersson, Borje S., additional, Mendrzyk, Regina, additional, Alpert, Amir, additional, Wagner, Claudia, additional, Nowak, Anna, additional, Aslan, Katrin, additional, Satelli, Arun, additional, Richter, Fabian, additional, Kuttruff-Coqui, Sabrina, additional, Schoor, Oliver, additional, Fritsche, Jens, additional, Coughlin, Zoe, additional, Mohamed, Ali S., additional, Sieger, Kerry, additional, Norris, Becky, additional, Ort, Rita, additional, Beck, Jennifer, additional, Vo, Henry Hiep, additional, Hoffgaard, Franziska, additional, Ruh, Manuel, additional, Backert, Linus, additional, Wistuba, Ignacio I., additional, Fuhrmann, David, additional, Ibrahim, Nuhad K., additional, Morris, Van Karlyle, additional, Kee, Bryan K., additional, Halperin, Daniel M., additional, Nogueras-Gonzalez, Graciela M., additional, Kebriaei, Partow, additional, Shpall, Elizabeth J., additional, Vining, David, additional, Hwu, Patrick, additional, Singh, Harpreet, additional, Reinhardt, Carsten, additional, Britten, Cedrik M., additional, Hilf, Norbert, additional, Weinschenk, Toni, additional, Maurer, Dominik, additional, and Walter, Steffen, additional

Published
2023
Full Text
View/download PDF

13. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Author

Rini, Brian I, Stenzl, Arnulf, Zdrojowy, Romauld, Kogan, Mikhail, Shkolnik, Mikhail, Oudard, Stephane, Weikert, Steffen, Bracarda, Sergio, Crabb, Simon J, Bedke, Jens, Ludwig, Joerg, Maurer, Dominik, Mendrzyk, Regina, Wagner, Claudia, Mahr, Andrea, Fritsche, Jens, Weinschenk, Toni, Walter, Steffen, Kirner, Alexandra, Singh-Jasuja, Harpreet, Reinhardt, Carsten, and Eisen, Tim

Published
2016
Full Text
View/download PDF

14. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Author

Hilf, Norbert, Kuttruff-Coqui, Sabrina, Frenzel, Katrin, Bukur, Valesca, Stevanović, Stefan, Gouttefangeas, Cecile, Platten, Michael, Tabatabai, Ghazaleh, Dutoit, Valerie, van der Burg, Sjoerd H., Straten, Per thor, Martinez-Ricarte, Francisco, Ponsati, Berta, Okada, Hideho, Lassen, Ulrik, Admon, Arie, Ottensmeier, Christian H., Ulges, Alexander, Kreiter, Sebastian, von Deimling, Andreas, Skardelly, Marco, Migliorini, Denis, Kroep, Judith R., Idorn, Manja, Rodon, Jordi, Piro, Jordi, Poulsen, Hans S., Shraibman, Bracha, McCann, Katy, Mendrzyk, Regina, Lower, Martin, Stieglbauer, Monika, Britten, Cedrik M., Capper, David, Welters, Marij J. P., Sahuquillo, Juan, Kiesel, Katharina, Derhovanessian, Evelyna, Rusch, Elisa, Bunse, Lukas, Song, Colette, Heesch, Sandra, Wagner, Claudia, Kemmer-Bruck, Alexandra, Ludwig, Jorg, Castle, John C., Schoor, Oliver, Tadmor, Arbel D., Green, Edward, Fritsche, Jens, Meyer, Miriam, Pawlowski, Nina, Dorner, Sonja, Hoffgaard, Franziska, Rossler, Bernhard, Maurer, Dominik, Weinschenk, Toni, Reinhardt, Carsten, Huber, Christoph, Rammensee, Hans-Georg, Singh-Jasuja, Harpreet, Sahin, Ugur, Dietrich, Pierre-Yves, and Wick, Wolfgang

Published
2019
Full Text
View/download PDF

15. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

Author

Löffler, Markus W., primary, Gori, Stefania, additional, Izzo, Francesco, additional, Mayer-Mokler, Andrea, additional, Ascierto, Paolo A., additional, Königsrainer, Alfred, additional, Ma, Yuk Ting, additional, Sangro, Bruno, additional, Francque, Sven, additional, Vonghia, Luisa, additional, Inno, Alessandro, additional, Avallone, Antonio, additional, Ludwig, Jörg, additional, Alcoba, Diego Duarte, additional, Flohr, Christian, additional, Aslan, Katrin, additional, Mendrzyk, Regina, additional, Schuster, Heiko, additional, Borrelli, Marco, additional, Valmori, Danila, additional, Chaumette, Tanguy, additional, Heidenreich, Regina, additional, Gouttefangeas, Cécile, additional, Forlani, Greta, additional, Tagliamonte, Maria, additional, Fusco, Caterina, additional, Penta, Roberta, additional, Iñarrairaegui, Mercedes, additional, Gnad-Vogt, Ulrike, additional, Reinhardt, Carsten, additional, Weinschenk, Toni, additional, Accolla, Roberto S., additional, Singh-Jasuja, Harpreet, additional, Rammensee, Hans-Georg, additional, and Buonaguro, Luigi, additional

Published
2022
Full Text
View/download PDF

16. 959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

Author

Wermke, Martin, primary, Tsimberidou, Apostolia-Maria, additional, Mohamed, Ali, additional, Mayer-Mokler, Andrea, additional, Satelli, Arun, additional, Reinhardt, Carsten, additional, Araujo, Dejka, additional, Maurer, Dominik, additional, Blumenschein, George Jr, additional, Singh, Harpreet, additional, Luke, Jason, additional, Guenther, Kerstin, additional, Kalra, Mamta, additional, Chatterjee, Manik, additional, Hilf, Norbert, additional, Mendrzyk, Regina, additional, Walter, Steffen, additional, Eck, Stephen, additional, Holderried, Tobias AW, additional, Weinschenk, Toni, additional, Morris, Van, additional, Alsdorf, Winfried, additional, and Britten, Cedrik M, additional

Published
2021
Full Text
View/download PDF

17. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Author

Walter, Steffen, Weinschenk, Toni, Stenzl, Arnulf, Zdrojowy, Romuald, Pluzanska, Anna, Szczylik, Cezary, Staehler, Michael, Brugger, Wolfram, Dietrich, Pierre-Yves, Mendrzyk, Regina, Hilf, Norbert, Schoor, Oliver, Fritsche, Jens, Mahr, Andrea, Maurer, Dominik, Vass, Verona, Trautwein, Claudia, Lewandrowski, Peter, Flohr, Christian, Pohla, Heike, Stanczak, Janusz J., Bronte, Vincenzo, Mandruzzato, Susanna, Biedermann, Tilo, Pawelec, Graham, Derhovanessian, Evelyna, Yamagishi, Hisakazu, Miki, Tsuneharu, Hongo, Fumiya, Takaha, Natsuki, Hirakawa, Kosei, Tanaka, Hiroaki, Stevanovic, Stefan, Frisch, Jurgen, Mayer-Mokler, Andrea, Kirner, Alexandra, Rammensee, Hans-Georg, Reinhardt, Carsten, and Singh-Jasuja, Harpreet

Subjects
Cyclophosphamide -- Dosage and administration, Polypeptides -- Health aspects, Immune response -- Research, Cancer vaccines -- Dosage and administration, Biological sciences, Health
Abstract

IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02+ subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)+ regulatory T ([T.sub.reg]) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of [T.sub.reg] cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing., Therapeutic cancer vaccines hold the promise of combining meaningful efficacy (prolongation of survival) with very good safety and tolerability, as has been shown in several recent randomized trials. (1-3) However, [...]

Published
2012
Full Text
View/download PDF

18. 293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)

Author

Tsimberidou, Apostolia, primary, Guenther, Kerstin, additional, Alpert, Amir, additional, Andersson, Borje, additional, Coughlin, Zoe, additional, Fritsche, Jens, additional, Hilf, Norbert, additional, Hwu, Patrick, additional, Kalra, Mamta, additional, Kuttruff-Coqui, Sabrina, additional, Maurer, Dominik, additional, Mendrzyk, Regina, additional, Mohamed, Ali, additional, Norris, Becky, additional, Nowak, Anna, additional, Ort, Rita, additional, Reinhardt, Carsten, additional, Richter, Fabian, additional, Satelli, Arun, additional, Schoor, Oliver, additional, Sieger, Kerry, additional, Singh, Harpreet, additional, Vining, David, additional, Wagner, Claudia, additional, Weinschenk, Toni, additional, Yee, Cassian, additional, and Walter, Steffen, additional

Published
2020
Full Text
View/download PDF

19. Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma

Author

Ulges, Alexander, primary, Hilf, Norbert, additional, Wick, Wolfgang, additional, Platten, Michael, additional, Dietrich, Pierre-Yves, additional, Frenzel, Katrin, additional, Admon, Arie, additional, Burg, Sjoerd S.H. van der, additional, Deimling, Andreas von, additional, Straten, Per thor, additional, Gouttefangeas, Cecile, additional, Kroep, Judith R., additional, Martínez-Ricarte, Francisco, additional, Okada, Hideo, additional, Ottensmeier, Christian H., additional, Ponsati, Berta, additional, Poulsen, Hans S., additional, Stevanovic, Stefan, additional, Tabatabai, Ghazaleh, additional, Rammensee, Hans-Georg, additional, Sahin, Ugur, additional, Maurer, Dominik, additional, and Mendrzyk, Regina, additional

Published
2019
Full Text
View/download PDF

21. Actively personalized vaccination trial for newly diagnosed glioblastoma

Author

Hilf, Norbert, primary, Kuttruff-Coqui, Sabrina, additional, Frenzel, Katrin, additional, Bukur, Valesca, additional, Stevanović, Stefan, additional, Gouttefangeas, Cécile, additional, Platten, Michael, additional, Tabatabai, Ghazaleh, additional, Dutoit, Valerie, additional, van der Burg, Sjoerd H., additional, thor Straten, Per, additional, Martínez-Ricarte, Francisco, additional, Ponsati, Berta, additional, Okada, Hideho, additional, Lassen, Ulrik, additional, Admon, Arie, additional, Ottensmeier, Christian H., additional, Ulges, Alexander, additional, Kreiter, Sebastian, additional, von Deimling, Andreas, additional, Skardelly, Marco, additional, Migliorini, Denis, additional, Kroep, Judith R., additional, Idorn, Manja, additional, Rodon, Jordi, additional, Piró, Jordi, additional, Poulsen, Hans S., additional, Shraibman, Bracha, additional, McCann, Katy, additional, Mendrzyk, Regina, additional, Löwer, Martin, additional, Stieglbauer, Monika, additional, Britten, Cedrik M., additional, Capper, David, additional, Welters, Marij J. P., additional, Sahuquillo, Juan, additional, Kiesel, Katharina, additional, Derhovanessian, Evelyna, additional, Rusch, Elisa, additional, Bunse, Lukas, additional, Song, Colette, additional, Heesch, Sandra, additional, Wagner, Claudia, additional, Kemmer-Brück, Alexandra, additional, Ludwig, Jörg, additional, Castle, John C., additional, Schoor, Oliver, additional, Tadmor, Arbel D., additional, Green, Edward, additional, Fritsche, Jens, additional, Meyer, Miriam, additional, Pawlowski, Nina, additional, Dorner, Sonja, additional, Hoffgaard, Franziska, additional, Rössler, Bernhard, additional, Maurer, Dominik, additional, Weinschenk, Toni, additional, Reinhardt, Carsten, additional, Huber, Christoph, additional, Rammensee, Hans-Georg, additional, Singh-Jasuja, Harpreet, additional, Sahin, Ugur, additional, Dietrich, Pierre-Yves, additional, and Wick, Wolfgang, additional

Published
2018
Full Text
View/download PDF

22. Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide

Author

Walter, Steffen, primary, Weinschenk, Toni, additional, Stenzl, Arnulf, additional, Zdrojowy, Romuald, additional, Pluzanska, Anna, additional, Szczylik, Cezary, additional, Staehler, Michael, additional, Brugger, Wolfram, additional, Dietrich, Pierre-Yves, additional, Hilf, Norbert, additional, Schoor, Oliver, additional, Fritsche, Jens, additional, Mahr, Andrea, additional, Mendrzyk, Regina, additional, Maurer, Dominik, additional, Vass, Verona, additional, Trautwein, Claudia, additional, Lewandrowski, Peter, additional, Flohr, Christian, additional, Pohla, Heike, additional, Stanczak, Janusz J., additional, Bronte, Vincenzo, additional, Mandruzzato, Susanna, additional, Biedermann, Tilo, additional, Pawelec, Graham, additional, Derhovanessian, Evelyna, additional, Yamagishi, Hisakazu, additional, Miki, Tsuneharu, additional, Hongo, Fumiya, additional, Takaha, Natsuki, additional, Hirakawa, Kosei, additional, Tanaka, Hiroaki, additional, Stevanovic, Stefan, additional, Rammensee, Hans-Georg, additional, Frisch, Jürgen, additional, Mayer-Mokler, Andrea, additional, Kirner, Alexandra, additional, Finke, James, additional, Rini, Brian, additional, Reinhardt, Carsten, additional, and Singh, Harpreet, additional

Published
2012
Full Text
View/download PDF

23. Abstract 302: Multiple distinct populations of myeloid derived suppressor cells in IMA901 treated renal cell cancer patients correlate with survival and with T-cell dysfunctions

Author

Walter, Steffen, primary, Hilf, Norbert, additional, Mendrzyk, Regina, additional, Maurer, Dominik, additional, Weinschenk, Toni, additional, Kirner, Alexandra, additional, Bronte, Vincenzo, additional, Mandruzzato, Susanna, additional, Stenzl, Arnulf, additional, Reinhardt, Carsten, additional, and Singh, Harpreet, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results